Volume | 44,830 |
|
|||||
News | - | ||||||
Day High | 13.23 | Low High |
|||||
Day Low | 10.98 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Avalo Therapeutics Inc | AVTX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.98 | 10.98 | 13.23 | 13.10 | 11.15 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
818 | 44,830 | $ 12.07 | $ 541,223 | - | 3.9501 - 1,130.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:44:17 | 99 | $ 12.14 | USD |
Avalo Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.35M | 801.61k | - | 1.92M | -31.54M | -39.35 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Avalo Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AVTX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 9.64 | 13.23 | 8.9174 | 10.52 | 35,204 | 3.46 | 35.89% |
1 Month | 15.00 | 17.49 | 8.9174 | 12.91 | 54,090 | -1.90 | -12.67% |
3 Months | 4.37 | 34.46 | 4.3039 | 19.32 | 716,291 | 8.73 | 199.77% |
6 Months | 21.36 | 34.46 | 3.9501 | 14.55 | 7,243,377 | -8.26 | -38.67% |
1 Year | 708.00 | 1,130.40 | 3.9501 | 33.15 | 23,489,573 | -694.90 | -98.15% |
3 Years | 688.80 | 1,711.20 | 3.9501 | 39.32 | 8,717,447 | -675.70 | -98.10% |
5 Years | 688.80 | 1,711.20 | 3.9501 | 39.32 | 8,717,447 | -675.70 | -98.10% |
Avalo Therapeutics Description
Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. |